This article is for informational and educational purposes only and does not constitute medical advice. BPC-157 is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a partial sequence of a protein found in human gastric juice. It has been investigated in a substantial body of preclinical research — primarily rodent models — for effects on angiogenesis, tissue repair, gastrointestinal cytoprotection, and neurological signaling. Proposed mechanisms reported in preclinical studies include VEGF upregulation, nitric oxide pathway modulation, FAK-paxillin cytoskeletal signaling, and growth hormone receptor sensitization. Human clinical trial data is limited; the compound is not approved by any regulatory agency for human use. The majority of published BPC-157 research originates from a single research group, which is an important consideration when evaluating the breadth of the evidence base.
1. Background
1.1 Origin and Discovery
BPC-157 was first described in research emerging from the University of Zagreb, Croatia, under the direction of Professor Predrag Sikiric. The compound was isolated as a partial sequence of a larger protein — referred to as body protection compound (BPC) — identified in human gastric juice. BPC-157 was originally reported as a fragment derived from a gastric protein complex referred to as Body Protection Compound (BPC), though the larger parent protein has not been as thoroughly characterized as the derived peptide fragment itself.
The 15-amino acid fragment designated BPC-157 was found to retain and concentrate the biological activity of the parent protein in preclinical assays. Its small size, defined sequence, and relative stability compared to other endogenous peptides made it amenable to synthesis and experimental use [1].
1.2 Research Context
BPC-157 has accumulated one of the larger preclinical literature bases among peptides of its class. Rodent model studies have examined its activity across a wide range of tissues and injury types, including gastric ulcer models, tendon transection, ligament injury, bone defects, corneal wounds, and various pharmacological insult models. The compound has also been studied under the designation PL-10, PL 14736, and bepecin, with limited early-phase human data from topical formulation trials in inflammatory bowel disease and wound healing contexts [2].
A defining feature of the BPC-157 literature is its concentration within a single research group. While this reflects sustained and productive investigation, it also limits independent replication — a standard scientific requirement for establishing robust mechanistic conclusions. This is addressed in detail in the limitations section.
2. Molecular Structure and Stability
BPC-157 is a 15-amino acid synthetic peptide with the following primary sequence:
A notable property of BPC-157 relative to other research peptides is its stability in acidic environments. While most peptides are rapidly degraded by gastric proteases and low pH, the proline-rich central region of BPC-157 limits enzymatic cleavage, reflecting the compound's origin in a protein that is itself resident in the gastric environment [1].
BPC-157 does not currently have an identified single primary receptor. Its pleiotropic activity across multiple tissue types and signaling systems is believed to arise from interactions with several distinct molecular targets, rather than from high-affinity binding to a single receptor — a mechanistic feature that distinguishes it from conventional pharmaceutical agents and complicates standard receptor pharmacology characterization.
3. Proposed Mechanisms of Action
Because no single receptor has been identified as the primary mediator of BPC-157's effects, the mechanistic literature describes a set of proposed pathways supported to varying degrees by in vitro and animal model data. The four most consistently reported mechanisms are summarized below.
3.1 VEGF and Angiogenesis
Angiogenesis — the formation of new blood vessels from existing vasculature — is a rate-limiting step in many tissue repair processes. Adequate vascularization is necessary for delivering oxygen and nutrients to healing tissue and for the recruitment of repair-mediating cell populations. BPC-157 has been reported in multiple rodent wound and tendon models to promote VEGF expression and to accelerate neovascularization at injury sites [3].
In vitro assays using human umbilical vein endothelial cells (HUVECs) have documented BPC-157-associated increases in endothelial cell migration and tube formation — both standard assays for angiogenic activity. The compound has also been reported to upregulate VEGFR2 (kinase insert domain receptor, KDR), the primary signaling receptor for VEGF-A, suggesting sensitization of the angiogenic response rather than simple ligand mimicry [3].
3.2 Nitric Oxide Pathway
Nitric oxide plays a central role in vascular tone regulation, gastric mucosal defense, and neuroprotection. BPC-157's interaction with the NO system is among the most consistently cited mechanisms in the literature, though the direction and nature of this interaction appears context-dependent.
In gastric cytoprotection models, BPC-157 has been reported to preserve NO production under conditions of mucosal insult (NSAIDs, ethanol, stress), countering the NO depletion that accompanies ulcer formation [4]. In vascular models, NO-mediated vasodilation may contribute to the perfusion effects observed in ischemia-reperfusion studies. The compound has also been reported to counteract L-NAME (an NOS inhibitor) and to interact with both eNOS and nNOS, though the precise binding mechanism at these enzymes is not established.
3.3 FAK-Paxillin Pathway
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that integrates signals from integrins and growth factor receptors to regulate cell adhesion, migration, proliferation, and survival. Paxillin is an adaptor protein that localizes to focal adhesions and acts downstream of FAK to coordinate cytoskeletal reorganization.
Chang and colleagues reported that BPC-157 was associated with activation of the FAK-paxillin pathway in tendon fibroblasts and endothelial cells, with increased cell migration observed in scratch assays and improved survival under serum-depleted conditions in these in vitro models [5]. This pathway may represent a convergence point through which BPC-157 influences multiple tissue types, given the ubiquitous expression of FAK across cell lineages relevant to tissue repair.
3.4 Growth Hormone Receptor Upregulation
In tendon fibroblast experiments, Chang and colleagues also reported that BPC-157 increases the expression of the growth hormone receptor (GHR) on the cell surface, without directly binding GH or IGF-1 [6]. This sensitization of the GHR may amplify the anabolic effects of endogenous GH signaling at the site of tendon injury, providing a plausible mechanism for accelerated matrix synthesis and repair observed in tendon injury models. This finding requires replication by independent groups before it can be considered an established mechanism.
3.5 EGR-1 Transcription Factor
Early growth response protein 1 (EGR-1) is a transcription factor involved in the regulation of genes associated with wound healing, inflammation resolution, and collagen synthesis. Research by Tkalcevic and colleagues using a topical formulation (PL 14736) reported upregulation of EGR-1 expression in healing wound tissue, associated with improved granulation tissue formation and collagen organization [7]. EGR-1 may serve as a downstream effector linking BPC-157's upstream signaling activity to transcriptional changes in repair-associated genes.
4. Key Preclinical Research Findings
| Research Area | Primary Model(s) | Evidence Level | Key Reported Effects |
|---|---|---|---|
| GI Cytoprotection | Rat ulcer models (NSAID, ethanol, stress) | Preclinical — Strong | Accelerated mucosal healing, NO preservation, reduced lesion size |
| Tendon Repair | Rat Achilles tendon transection | Preclinical — Moderate–Strong | Improved tendon strength, enhanced fibroblast outgrowth, GHR upregulation |
| Wound Healing | Rat excision/incision, HUVEC in vitro | Preclinical — Moderate | Accelerated re-epithelialization, VEGF/angiogenesis upregulation, EGR-1 |
| Muscle Repair | Rat muscle crush / laceration | Preclinical — Limited–Moderate | Reduced inflammatory infiltrate, improved functional recovery timelines |
| Bone Healing | Rat segmental defect models | Preclinical — Moderate | Enhanced callus formation, improved mineralization at defect sites |
| Neurological | Rat dopamine/serotonin pharmacological models | Preclinical — Limited | Modulation of dopaminergic/serotonergic signaling, counteraction of drug-induced effects |
| Human (Topical) | Phase I/II IBD fistula, skin wound trials | Human — Limited | Some tolerability and preliminary efficacy signals; trials small and early-stage |
4.1 Gastrointestinal Cytoprotection
The strongest and most replicated body of BPC-157 preclinical research relates to its origin system: the gastrointestinal tract. In rat models of gastric ulceration induced by NSAIDs (indomethacin, aspirin), ethanol, and restraint stress, systemic and intragastric administration of BPC-157 has consistently been associated with reduced lesion area, accelerated mucosal restitution, and preservation of mucosal blood flow [4].
Proposed mechanisms in the gastric context include NO pathway preservation, maintenance of prostaglandin-independent mucosal defense, and promotion of angiogenesis in the lamina propria underlying the ulcer base. The compound has also been reported to counteract the damaging effects of NSAID-induced downregulation of COX-1-dependent prostaglandin synthesis, though it does not appear to directly inhibit or activate cyclooxygenase enzymes.
Separately, a topical formulation designated PL 14736 (bepecin) entered early-phase human trials for inflammatory bowel disease and cutaneous fistula healing. Available data reported preliminary safety and activity signals in the fistula indication; however, these trials were small, and the topical route differs meaningfully from the systemic routes studied in animal models [2].
4.2 Tendon and Musculoskeletal Repair
Tendon healing is a slow process limited by the poor vascularity of tendon tissue, the low metabolic activity of tenocytes, and the tendency toward scar-dominant repair rather than functional collagen realignment. BPC-157 has been extensively studied in rat Achilles tendon transection models, with reports of accelerated functional recovery, improved tendon morphology, and enhanced biomechanical properties in treated animals [5].
Chang and colleagues reported that BPC-157 was associated with increased tendon cell (tenocyte) outgrowth from tissue explants, improved cell survival under oxidative stress conditions, and enhanced migration of fibroblasts and endothelial cells via FAK-paxillin pathway activation in these in vitro models. Concurrent upregulation of VEGF and GHR observed in these models was interpreted as suggesting convergent pro-repair signaling, though this interpretation has not been independently verified [5,6].
Similar findings have been reported in ligament injury models (medial collateral ligament) and muscle laceration models, though these are generally less extensively characterized than the tendon transection data.
4.3 Wound Healing and Angiogenesis
In excision and incision wound models in rats, BPC-157 administration has been associated with accelerated re-epithelialization, reduced wound area at matched time points, and improved tensile strength of healed tissue. Histological analyses have reported increased granulation tissue formation and more organized collagen deposition in treated animals compared to controls [7].
The EGR-1 data from Tkalcevic and colleagues is notable in this context: EGR-1 is a transcription factor known to regulate genes including PDGF-A, TGF-β1, FGF-2, and VEGF — all of which are implicated in wound healing cascades. Upregulation of EGR-1 by BPC-157 may therefore provide a transcriptional framework through which the compound coordinately activates multiple repair-associated gene programs [7].
4.4 Neurological Signaling Models
A body of research from the Sikiric group has examined BPC-157 in pharmacological models of CNS dysfunction, including dopamine system perturbations (6-OHDA, haloperidol, amphetamine models) and serotonin system interactions. BPC-157 has been reported to attenuate or reverse certain drug-induced behavioral and neurochemical abnormalities in rat models [8].
These findings suggest that BPC-157 may interact with monoaminergic neurotransmitter systems, though the specific molecular mechanisms are not clearly established. Whether these effects reflect direct CNS receptor activity, indirect modulation via peripheral-to-central signaling (e.g., through the brain-gut axis and vagal afferents), or non-specific neuroprotective effects of improved tissue perfusion remains an open research question. These neurological findings have seen limited independent replication outside the originating research group.
| Study Focus | Model | Route | Primary Finding | Reference |
|---|---|---|---|---|
| Tendon outgrowth / cell survival | In vitro (rat tendon explant, HUVEC) | Cell culture | Increased tenocyte outgrowth; FAK-paxillin activation; improved survival under oxidative stress | [5] |
| GHR expression in tendon fibroblasts | In vitro (rat tendon fibroblasts) | Cell culture | Increased GH receptor expression; potentiation of GH-dependent signaling | [6] |
| Wound healing / EGR-1 | Rat excision wound | Topical (PL 14736) | EGR-1 upregulation; improved granulation tissue formation and collagen organization | [7] |
| Gastric ulcer (NSAID) | Rat indomethacin ulcer | IP / intragastric | Reduced lesion area; preserved mucosal blood flow; NO pathway involvement | [4] |
| Brain-gut axis / dopamine | Rat 6-OHDA model | IP | Attenuation of dopaminergic lesion effects; behavioral normalization | [8] |
| IBD / fistula (human) | Phase I/II trial (topical, PL 14736) | Topical | Preliminary tolerability and activity signals; small trial; limited conclusions | [2] |
5. Limitations of Current Research
References
- Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612–1632. doi:10.2174/138161211796196954
- Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia): novel therapy in GI tract." J Physiol Pharmacol. 2006;57(Suppl 12):67–69.
- Hsieh MJ, Liu HT, Wang CN, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." J Mol Med. 2017;95(3):323–333. doi:10.1007/s00109-016-1488-y
- Sikiric P, Seiwerth S, Rucman R, et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design. 2013;19(1):76–83. doi:10.2174/138161213804143495
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774–780. doi:10.1152/japplphysiol.00945.2010
- Chang CH, Tsai WC, Hsu YH, Pang JH. "Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts." Molecules. 2014;19(11):19066–19077. doi:10.3390/molecules191119066
- Tkalcevic VI, Cuzic S, Brajsa K, et al. "Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression." European Journal of Pharmacology. 2007;570(1–3):212–221. doi:10.1016/j.ejphar.2007.05.072
- Sikiric P, Seiwerth S, Rucman R, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Current Neuropharmacology. 2016;14(8):857–865. doi:10.2174/1570159X13666160502153238